Advanced search×

Genetic approaches to understanding human obesity.

J Clin Invest 121(6):2080-6 (2011) PMID 21633175

Obesity and its associated comorbidities represent one of the biggest public health challenges facing the world today. The heritability of body weight is high, and genetic variation plays a major role in determining the interindividual differences in susceptibility or resistance to the obesogenic environment. Here we discuss how genetic studies in humans have contributed to our understanding of the central pathways that govern energy homeostasis. We discuss how the arrival of technological advances such as next-generation sequencing will result in a major acceleration in the pace of gene discovery. The study of patients harboring these genetic variants has informed our understanding of the molecular and physiological pathways involved in energy homeostasis. We anticipate that future studies will provide the framework for the development of a more rational targeted approach to the prevention and treatment of genetically susceptible individuals.

DOI: 10.1172/JCI46044
Version: za2963e q8zae q8zbd q8zc5 q8zd2 q8ze0 q8zfd q8zg0

Similar articles you may find interesting…

  1. Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.

    J Clin Invest 121(7):2554-69 (2011) PMID 21670504

    We used Stat1-deficient mice to test the role of donor Stat1 in MHC-matched minor histocompatibility antigen-mismatched (mHA-mismatched) and fully MHC-mismatched models of bone marrow transplantation. Lack of Stat1 in donor splenocytes reduced graft-versus-host disease (GVHD) in both immunogenetic d...
  2. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

    J Clin Invest 121(4):1231-41 (2011) PMID 21490404

    We provide a brief overview of the signaling pathways up- and downstream of mTORC1 and -2, and discuss the insights into therapeutic anticancer targets - both those that have been tried in the clinic with limited success and those currently under clinical development - that knowledge of these pathwa...
  3. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

    J Clin Invest 121(4):1231-41 (2011) PMID 21490404

    We provide a brief overview of the signaling pathways up- and downstream of mTORC1 and -2, and discuss the insights into therapeutic anticancer targets - both those that have been tried in the clinic with limited success and those currently under clinical development - that knowledge of these pathwa...